{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:54:46Z","timestamp":1791431686515,"version":"4.3.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"DOI":"10.1007\/s12185-026-04280-5","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:39:51Z","timestamp":1791430791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical impact of infused CD3-positive cell dose in unrelated peripheral blood stem cell transplantation"],"prefix":"10.1007","author":[{"given":"Yasutaka","family":"Sadaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairi","family":"Kojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riki","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Hasunuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hatsusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takeyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Jinguji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Toubai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Haraguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"4280_CR1","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","volume":"4","author":"O Penack","year":"1980","unstructured":"Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 1980;4:6283\u201390.","journal-title":"Blood Adv"},{"key":"4280_CR2","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s41409-025-02625-y","volume":"60","author":"S Kurosawa","year":"2025","unstructured":"Kurosawa S, Kojo K, Yamakawa R, Kato K, Sadaga Y, Kondo K, et al. Improved non-relapse mortality in allogeneic hematopoietic stem cell transplantation: a long-standing multidisciplinary pursuit at a single center. Bone Marrow Transplant. 2025;60:1193\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"4280_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","volume":"55","author":"J Styczy\u0144ski","year":"2020","unstructured":"Styczy\u0144ski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020;55:126\u201336.","journal-title":"Bone Marrow Transplant"},{"key":"4280_CR4","volume":"11","author":"S Kiene","year":"2024","unstructured":"Kiene S, Albrecht M, Theurich S, Scheid C, Skoetz N, Holtick U. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev. 2024;11:CD010189.","journal-title":"Cochrane Database Syst Rev"},{"key":"4280_CR5","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487\u201396.","journal-title":"N Engl J Med"},{"key":"4280_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12185-019-02672-4","volume":"110","author":"H Yamamoto","year":"2019","unstructured":"Yamamoto H. Single cord blood transplantation in Japan; expanding the possibilities of CBT. Int J Hematol. 2019;110:39\u201349.","journal-title":"Int J Hematol"},{"key":"4280_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/978-3-031-44080-9_43","volume-title":"The EBMT handbook","author":"E Holler","year":"2024","unstructured":"Holler E, Greinix H, Zeiser R. Acute graft-versus-host disease. In: The EBMT handbook. Cham: Springer International Publishing; 2024. p. 385\u201393."},{"key":"4280_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/978-3-031-44080-9_44","volume-title":"The EBMT handbook","author":"D Wolff","year":"2024","unstructured":"Wolff D, Peric Z, Lawitschka A. Chronic graft-versus-host disease. In: The EBMT handbook. Cham: Springer International Publishing; 2024. p. 395\u2013410."},{"key":"4280_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12185-017-2341-y","volume":"107","author":"T Goto","year":"2018","unstructured":"Goto T, Tanaka T, Sawa M, Ueda Y, Ago H, Chiba S, et al. Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. Int J Hematol. 2018;107:211\u201321.","journal-title":"Int J Hematol"},{"key":"4280_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jcyt.2023.11.012","volume":"26","author":"H Hayashi","year":"2024","unstructured":"Hayashi H, Iwasaki M, Nakasone H, Tanoshima R, Shimabukuro M, Takeda W, et al. Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor\/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy. Cytotherapy. 2024;26:178\u201384.","journal-title":"Cytotherapy"},{"key":"4280_CR11","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1001\/jamaoncol.2016.2520","volume":"2","author":"SJ Lee","year":"2016","unstructured":"Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, et al. Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial: long-term follow-up of a randomized clinical trial. JAMA Oncol. 2016;2:1583\u20139.","journal-title":"JAMA Oncol"},{"key":"4280_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1365-2796.2012.02547.x","volume":"272","author":"O Ringd\u00e9n","year":"2012","unstructured":"Ringd\u00e9n O, Labopin M, Beelen DW, Volin L, Ehninger G, Finke J, et al. Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients: blood or marrow in MUD transplantation for AML. J Intern Med. 2012;272:472\u201383.","journal-title":"J Intern Med"},{"key":"4280_CR13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2023020073","volume":"142","author":"O Jamy","year":"2023","unstructured":"Jamy O, Zeiser R, Chen Y-B. Novel developments in the prophylaxis and treatment of acute GVHD. Blood. 2023;142:1037\u201346.","journal-title":"Blood"},{"key":"4280_CR14","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41409-024-02370-8","volume":"59","author":"G Vadakkel","year":"2024","unstructured":"Vadakkel G, Eng S, Proli A, Ponce DM. Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era. Bone Marrow Transplant. 2024;59:1360\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"4280_CR15","doi-asserted-by":"publisher","first-page":"1339318","DOI":"10.3389\/fimmu.2024.1339318","volume":"15","author":"CP Pacini","year":"2024","unstructured":"Pacini CP, Soares MVD, Lacerda JF. The impact of regulatory T cells on the graft-versus-leukemia effect. Front Immunol. 2024;15:1339318.","journal-title":"Front Immunol"},{"key":"4280_CR16","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1182\/bloodadvances.2025016915","volume":"9","author":"T Hammoudi","year":"2025","unstructured":"Hammoudi T, Nucera S, Troullioud Lucas AG, Ansari M, Balduzzi A, Bertaina A, et al. Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group. Blood Adv. 2025;9:6141\u201357.","journal-title":"Blood Adv"},{"key":"4280_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2026.102347","volume":"94","author":"E Bembnista","year":"2026","unstructured":"Bembnista E, Matuszak P, \u0141ojko-Dankowska A, Dytfeld D, Matuszak M, Wache A, et al. CD34+\/CD3+ cells ratio in the peripheral blood stem cells product and graft-versus-host disease: is there still room for improvement? Transpl Immunol. 2026;94:102347.","journal-title":"Transpl Immunol"},{"key":"4280_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/09636897231157054","author":"P Jiang","year":"2023","unstructured":"Jiang P, Yu F, Xu X, Cai Y, Yang J, Tong Y, et al. Impact of lymphocyte subsets of grafts on the outcome of haploidentical peripheral blood stem cell transplantation. Cell Transplant. 2023. https:\/\/doi.org\/10.1177\/09636897231157054.","journal-title":"Cell Transplant"},{"key":"4280_CR19","doi-asserted-by":"publisher","first-page":"918.e1","DOI":"10.1016\/j.jtct.2021.08.008","volume":"27","author":"M Delia","year":"2021","unstructured":"Delia M, Carluccio P, Mestice A, Chiusolo P, Metafuni E, Bellesi S, et al. The impact of graft CD3 cell\/regulatory T cell ratio on acute graft-versus-host disease and post-transplantation outcome: a prospective multicenter study of patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation. Transplant Cell Ther. 2021;27:918.e1-918.e9.","journal-title":"Transplant Cell Ther"},{"key":"4280_CR20","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.bbmt.2016.03.009","volume":"22","author":"N Castillo","year":"2016","unstructured":"Castillo N, Garc\u00eda-Cadenas I, D\u00edaz-Heredia C, Martino R, Barba P, Ferr\u00e0 C, et al. Cord blood units with high CD3(+) cell counts predict early lymphocyte recovery after in vivo T cell-depleted single cord blood transplantation. Biol Blood Marrow Transplant. 2016;22:1073\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4280_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jcyt.2020.01.007","volume":"22","author":"L Teofili","year":"2020","unstructured":"Teofili L, Chiusolo P, Valentini CG, Metafuni E, Bellesi S, Orlando N, et al. Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes? Cytotherapy. 2020;22:158\u201365.","journal-title":"Cytotherapy"},{"key":"4280_CR22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41409-018-0380-5","volume":"54","author":"SS Patel","year":"2019","unstructured":"Patel SS, Rybicki LA, Corrigan D, Dumont C, Bolwell B, Dean R, et al. Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019;54:775\u201381.","journal-title":"Bone Marrow Transplant"},{"key":"4280_CR23","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41409-018-0183-8","volume":"53","author":"A Mussetti","year":"2018","unstructured":"Mussetti A, De Philippis C, Carniti C, Bastos-Oreiro M, Gayoso J, Cieri N, et al. CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant. 2018;53:1522\u201331.","journal-title":"Bone Marrow Transplant"},{"key":"4280_CR24","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.bbmt.2019.05.007","volume":"25","author":"A Saad","year":"2019","unstructured":"Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, et al. Impact of T cell dose on outcome of T cell-replete HLA-matched allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1875\u201383.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4280_CR25","doi-asserted-by":"publisher","first-page":"27255","DOI":"10.18632\/oncotarget.8463","volume":"7","author":"T Czerw","year":"2016","unstructured":"Czerw T, Labopin M, Schmid C, Cornelissen JJ, Chevallier P, Blaise D, et al. High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Oncotarget. 2016;7:27255\u201366.","journal-title":"Oncotarget"},{"key":"4280_CR26","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"4280_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","volume":"120","author":"P Armand","year":"2012","unstructured":"Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120:905\u201313.","journal-title":"Blood"},{"key":"4280_CR28","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"4280_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107704","volume":"153","author":"K Kondo","year":"2025","unstructured":"Kondo K, Najima Y, Sadato D, Hirama C, Kato K, Sadaga Y, et al. Pre-transplant blinatumomab and\/or inotuzumab ozogamicin therapy for relapsed\/refractory acute lymphoblastic and B\/myeloid mixed phenotype acute leukemia in adults. Leuk Res. 2025;153:107704.","journal-title":"Leuk Res"},{"key":"4280_CR30","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s12185-025-03951-z","volume":"121","author":"Y Masuda","year":"2025","unstructured":"Masuda Y, Sadato D, Toya T, Hosoda Y, Hirama C, Shimizu H, et al. Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients. Int J Hematol. 2025;121:820\u201332.","journal-title":"Int J Hematol"},{"key":"4280_CR31","doi-asserted-by":"publisher","first-page":"1045.e1","DOI":"10.1016\/j.jtct.2025.08.016","volume":"31","author":"S Kurosawa","year":"2025","unstructured":"Kurosawa S, Kato K, Sadaga Y, Kondo K, Sakai S, Kato C, et al. HCT-VTE-J model to predict late-onset venous thromboembolism after allogeneic hematopoietic stem cell transplantation: a Japanese single-center study. Transplant Cell Ther. 2025;31:1045.e1-1045.e13.","journal-title":"Transplant Cell Ther"},{"key":"4280_CR32","doi-asserted-by":"publisher","first-page":"121.e1","DOI":"10.1016\/j.jtct.2023.10.003","volume":"30","author":"N Shingai","year":"2024","unstructured":"Shingai N, Ota A, Kato K, Kondo K, Sadaga Y, Kato C, et al. Elevation of urinary liver-type fatty acid-binding protein is a harbinger of poor patient prognosis after allogeneic stem cell transplantation. Transplant Cell Ther. 2024;30:121.e1-121.e8.","journal-title":"Transplant Cell Ther"},{"key":"4280_CR33","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41409-024-02311-5","volume":"59","author":"S Kaito","year":"2024","unstructured":"Kaito S, Najima Y, Sadato D, Hirama C, Kishida Y, Nagata A, et al. Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies. Bone Marrow Transplant. 2024;59:1169\u201375.","journal-title":"Bone Marrow Transplant"},{"key":"4280_CR34","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41409-020-01016-9","volume":"56","author":"Y Najima","year":"2021","unstructured":"Najima Y, Sadato D, Harada Y, Oboki K, Hirama C, Toya T, et al. Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. Bone Marrow Transplant. 2021;56:334\u201346.","journal-title":"Bone Marrow Transplant"},{"key":"4280_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4280_CR36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12185-021-03233-4","volume":"115","author":"Y Yamada","year":"2022","unstructured":"Yamada Y, Ikegawa S, Najima Y, Atsuta Y, Konuma R, Adachi H, et al. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine\/low-dose melphalan plus 4 Gy TBI versus fludarabine\/ busulfan plus 4 Gy TBI. Int J Hematol. 2022;115:244\u201354.","journal-title":"Int J Hematol"},{"key":"4280_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/tid.70116","volume":"27","author":"Y Masuda","year":"2025","unstructured":"Masuda Y, Toya T, Yamakawa R, Kojo K, Kato K, Sadaga Y, et al. Real-world efficacy of extending duration of letermovir prophylaxis for allogeneic stem cell recipients. Transpl Infect Dis. 2025;27:e70116.","journal-title":"Transpl Infect Dis"},{"key":"4280_CR38","doi-asserted-by":"publisher","first-page":"463.e1","DOI":"10.1016\/j.jtct.2025.04.016","volume":"31","author":"K Kurihara","year":"2025","unstructured":"Kurihara K, Sadato D, Toya T, Hirama C, Kato K, Kondo K, et al. Recent advances in the prognosis of HHV-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2025;31:463.e1-463.e12.","journal-title":"Transplant Cell Ther"},{"key":"4280_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jgar.2023.02.001","volume":"32","author":"M Sakaguchi","year":"2023","unstructured":"Sakaguchi M, Atsuta Y, Sekiya N, Najima Y, Fukushima K, Shingai N, et al. Clinical impact and early prediction of carbapenem-resistant Pseudomonas aeruginosa bacteraemia in allogeneic hematopoietic stem cell transplantation recipients. J Glob Antimicrob Resist. 2023;32:187\u201394.","journal-title":"J Glob Antimicrob Resist"},{"key":"4280_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12185-021-03146-2","volume":"114","author":"T Konishi","year":"2021","unstructured":"Konishi T, Sekiya N, Otsuka Y, Konuma R, Wada A, Adachi H, et al. Changes in vaccination strategies contribute to the development of invasive pneumococcal disease in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study for promoting vaccination. Int J Hematol. 2021;114:263\u201370.","journal-title":"Int J Hematol"},{"key":"4280_CR41","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41409-019-0541-1","volume":"55","author":"S Kaito","year":"2020","unstructured":"Kaito S, Sekiya N, Najima Y, Suzuki T, Wada A, Adachi H, et al. Nutritional risk index as a risk factor for breakthrough candidemia in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;55:661\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"4280_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijid.2019.10.003","volume":"89","author":"S Kurosawa","year":"2019","unstructured":"Kurosawa S, Sekiya N, Doki N, Yaguchi T, Kishida Y, Nagata A, et al. The emergence of rare nocardiosis following allogeneic hematopoietic stem cell transplantation in the era of molecular taxonomy. Int J Infect Dis. 2019;89:154\u201362.","journal-title":"Int J Infect Dis"},{"key":"4280_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s12185-021-03234-3","volume":"115","author":"Y Yamada","year":"2022","unstructured":"Yamada Y, Konishi T, Nagata A, Toya T, Najima Y, Kobayashi T, et al. Letter to the editor: very low-dose antithymocyte globulin (thymoglobulin) is effective for steroid-refractory acute graft-versus-host disease involving the skin or gut after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022;115:449\u201351.","journal-title":"Int J Hematol"},{"key":"4280_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00277-016-2854-0","volume":"96","author":"K Hattori","year":"2017","unstructured":"Hattori K, Doki N, Kurosawa S, Hino Y, Yamamoto K, Sakaguchi M, et al. Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2017;96:319\u201321.","journal-title":"Ann Hematol"},{"key":"4280_CR45","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12185-016-1947-9","volume":"103","author":"K Kuriyama","year":"2016","unstructured":"Kuriyama K, Fuji S, Inamoto Y, Tajima K, Tanaka T, Inoue Y, et al. Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. Int J Hematol. 2016;103:453\u201360.","journal-title":"Int J Hematol"},{"key":"4280_CR46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3324\/haematol.2013.093062","volume":"99","author":"Y Inamoto","year":"2014","unstructured":"Inamoto Y, Martin PJ, Storer BE, Mielcarek M, Storb RF, Carpenter PA. Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease. Haematologica. 2014;99:385\u201391.","journal-title":"Haematologica"},{"key":"4280_CR47","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/1744-9987.70053","volume":"29","author":"S Kurosawa","year":"2025","unstructured":"Kurosawa S, Haraguchi K, Najima Y, Uchibori Y, Ishiwada M, Honma Y, et al. Real-world practice and challenges of donor lymphocyte apheresis and infusion: a single-center experience. Ther Apher Dial. 2025;29:782\u201391.","journal-title":"Ther Apher Dial"},{"key":"4280_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/1744-9987.14202","volume":"29","author":"S Kurosawa","year":"2025","unstructured":"Kurosawa S, Haraguchi K, Honma Y, Kawai F, Ishiwada M, Iimura R, et al. Improving cellular therapy operations through pre-harvest measurement of peripheral CD34-positive cell counts in allogeneic stem cell harvest. Ther Apher Dial. 2025;29:131\u201340.","journal-title":"Ther Apher Dial"},{"key":"4280_CR49","doi-asserted-by":"publisher","unstructured":"Uchibori Y, Kurosawa S, Najima Y, Haraguchi K, Sadato D, Hirama C, et al. Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience. Frontiers in immunology [Internet]. 2025 [cited 2026 Mar 11];16. Available from: https:\/\/doi.org\/10.3389\/fimmu.2025.1521895","DOI":"10.3389\/fimmu.2025.1521895"},{"key":"4280_CR50","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1182\/blood.2019000953","volume":"136","author":"T Toubai","year":"2020","unstructured":"Toubai T, Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. Blood. 2020;136:429\u201340.","journal-title":"Blood"},{"key":"4280_CR51","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2011-10-387357","volume":"119","author":"AC Harris","year":"2012","unstructured":"Harris AC, Ferrara JLM, Braun TM, Holler E, Teshima T, Levine JE, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012;119:2960\u20133.","journal-title":"Blood"},{"key":"4280_CR52","doi-asserted-by":"publisher","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","volume":"27","author":"BL Scott","year":"2021","unstructured":"Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, et al. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial. Transplant Cell Ther. 2021;27:483.e1-483.e6.","journal-title":"Transplant Cell Ther"},{"key":"4280_CR53","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"4280_CR54","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41409-023-02162-6","volume":"59","author":"J Sugita","year":"2024","unstructured":"Sugita J, Kuroha T, Ishikawa J, Eto T, Fukushima K, Yokota I, et al. Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor. Bone Marrow Transplant. 2024;59:344\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"4280_CR55","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jtct.2021.03.029","volume":"27","author":"J Pidala","year":"2020","unstructured":"Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIb. The 2020 preemptive therapy working group report. Transplant Cell Ther. 2020;27:632\u201341.","journal-title":"Transplant Cell Ther"},{"key":"4280_CR56","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","volume":"115","author":"JA Olson","year":"2010","unstructured":"Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115:4293\u2013301.","journal-title":"Blood"},{"key":"4280_CR57","doi-asserted-by":"publisher","first-page":"589.e1","DOI":"10.1016\/j.jtct.2022.06.007","volume":"28","author":"F Zhao","year":"2022","unstructured":"Zhao F, Shi Y, Chen X, Zhang R, Pang A, Zhai W, et al. Higher dose of CD34+ cells promotes early reconstitution of natural killer cells and is associated with better outcomes after unmanipulated hematopoietic stem cell transplantation for myeloid malignancies. Transplant Cell Ther. 2022;28:589.e1-589.e10.","journal-title":"Transplant Cell Ther"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04280-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04280-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04280-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:39:53Z","timestamp":1791430793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04280-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":57,"alternative-id":["4280"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04280-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no competing interests.","order":1,"name":"Ethics","label":"Conflicts of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}